A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Completed · Phase 2 · Has a placebo group

Conditions studied: Epilepsy

In brief

This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.

Key facts

Study ID

NCT00175825

Run by

UCB Pharma

People needed

210

Starts

2005-11-07

Expected to finish

2006-06-29

Last updated by the study team

2018-10-02

Who can join

Age: 16 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male/female from 16 to 65 years
• Well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
• History of partial onset seizures
• Subjects having at least 4 partial onset seizures during the 4-week Baseline Period and at least 2 partial onset seizures during the 3 months prior to Visit 1
• Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a stable dose.

You may not qualify if…

• Seizure type IA non-motor as only seizure type
• Seizures occurring only in clusters
• Status epilepticus during the last 2 years before Visit 1
• History of cerebrovascular accident (CVA)
• Presence of any sign suggesting rapidly progressing brain disorder or brain tumor

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Little Rock, Arkansas, United States
• Study site — Fresno, California, United States
• Study site — Bradenton, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Paducah, Kentucky, United States
• Study site — Ruston, Louisiana, United States
• Study site — Bethesda, Maryland, United States
• Study site — Burlington, Massachusetts, United States
• Study site — Grand Rapids, Michigan, United States
• Study site — Rochester, Minnesota, United States
• Study site — Tupelo, Mississippi, United States
• Study site — Chesterfield, Missouri, United States
• Study site — Great Falls, Montana, United States
• Study site — Englewood Cliffs, New Jersey, United States
• Study site — Toms River, New Jersey, United States
• Study site — New York, New York, United States
• Study site — Wilmington, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Woonsocket, Rhode Island, United States
• Study site — Greenville, South Carolina, United States
• Study site — Dallas, Texas, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.